Get started
Author

Alexandra Gabriela Ferreira

Observed names: Alexandra Ferreira, Alexandra G. Ferreira, Alexandra Gabriela. Ferreira
Institution: BioInvent (Sweden)
ORCID: 0000-0001-8918-1183
Observed ORCID: 0000-0001-8918-1183
OpenAlex ID: A5030099577
Direct reprogramming of fibroblasts into antigen-presenting dendritic cells
2018 · Fábio F. Rosa, Cristiana F. Pires, et al. · Science Immunology · 128
Restoring tumor immunogenicity with dendritic cell reprogramming
2023 · Olga Zimmermannova, Alexandra G. Ferreira, et al. · Science Immunology · 97
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
2021 · Olga Zimmermannova, Inês Caiado, et al. · Frontiers in Immunology · 58
PDF
Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells
2022 · Fábio F. Rosa, Cristiana F. Pires, et al. · Science Immunology · 54
GATA2 mitotic bookmarking is required for definitive haematopoiesis
2023 · Rita Silvério-Alves, Ilia Kurochkin, et al. · Nature Communications · 23
PDF
Reprogramming Cancer Cells to Antigen-presenting Cells
2023 · Alexandra Ferreira, Olga Zimmermannova, et al. · BIO-PROTOCOL · 9
Orchestrating an immune response to cancer with cellular reprogramming
2023 · Olga Zimmermannova, Alexandra Gabriela Ferreira, et al. · Genes and Immunity · 7
PDF
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
Abstract A40: Restoring tumor immunogenicity with dendritic cell reprogramming
2022 · Alexandra G. Ferreira, Olga Zimmermannova, et al. · Cancer Immunology Research · 1
Direct Reprogramming of Mouse and Human Fibroblasts into Conventional Dendritic Cells Type 1
2022 · Fábio F. Rosa, Cristiana F. Pires, et al. · Molecular Immunology · 1
Reprogramming Human Cancer Cells into Antigen Presentation
2021 · Olga Zimmermannova, Ilia Kurochkin, et al. · Blood · 1
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors
2026 · Ingrid Teige, Kristoffer S. Rohrberg, et al. · Clinical Cancer Research
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Materials and Methods from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Works count: 26
Citation count: 382
H-index: 7
I10-index: 5
Year
Topic
Type